ClearSight Therapeutics, Inc.

USPTO allows 26 claims for ophthalmic formulations containing quaternary chitosan derivatives, marking a key step toward U.S. patent protection.

Competitive National Eye Institute funding provides external validation of ClearSight's proposed scientific program and supports a one-year investigation of a preservative-free ophthalmic formulation in acute infectious conjunctivitis and epidemic...

Proposed five-year agreement positions Covalent Medical to commercialize ClearSight's OTC Artificial Tears+, Contact Lens Rewetting Drops, and Pink Eye portfolio across physician-dispensed and national retail channels, with launch targeted for Q1 2027...